Active substances
Caffeine + Codeine + Paracetamol
- SFDA 7
- Health Canada 5
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| FEVADOL PLUS TAB | 500,30,8 mg,mg,mg | Tablet · Oral use | 20 Blister | SAR 9.65 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Prodein Plus | 500,8,30 mg,mg,mg | Soluble tablet · Oral use | 20 Blister | SAR 10.50 | Generic · Prescription | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| SOLPADEINE CAPSULE | 500,30,8 mg,mg,mg | Capsule · Oral use | 20 Blister | SAR 13.15 | NCE · Prescription | ASPEN PHARMA TRADING LIMITED (APTL) | Valid |
| SOLPADEINE SOLUBLE TABLET | 500,30,8 mg,mg,mg | Soluble tablet · Oral use | 20 Blister | SAR 13.15 | Generic · Prescription | ASPEN PHARMA TRADING LIMITED (APTL) | Valid |
| ADOL COMPOUND TABLETS | 500, 50, 8 mg | Caplet · Oral use | 20 Blister | SAR 6.95 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| SOLPADEINE CAPSULE | 500, 30, 8 mg | Capsule · Oral use | 24 Blister | SAR 11.40 | NCE · OTC | GLAXOSMITHKLINE (GSK) | Withdrawn by MAH · Not Marketed |
| SOLPADEINE SOLUBLE TAB | 500, 30, 8 mg | Tablet · Oral use | 24 Blister | SAR 12.45 | Generic · OTC | GLAXOSMITHKLINE (GSK) | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ENTEROPATHIC ARTHROPATHIES, UNSPECIFIED SITE REACTIVE ARTHROPATHY, UNSPECIFIED; SICKLE CELL DISEASE - PAIN MANAGEMENT
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ACETAMINOPHEN WITH CODEINE - CAPLET | 02143933 | 8 MG; 300 MG; 15 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE TABLETS | 02154234 | 8 MG; 15 MG; 300 MG | TABLET · ORAL | LABORATOIRE RIVA INC. |
| TEVA-LENOLTEC NO. 1 | 00653233 | 15 MG; 300 MG; 8 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-LENOLTEC NO. 2 | 00653241 | 15 MG; 15 MG; 300 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-LENOLTEC NO. 3 | 00653276 | 15 MG; 300 MG; 30 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.